Tag: chemistry
-
Cannabinoid Synthesis Process Licensed to Spin-Off Company
A genetic technology for synthesizing cannabinoid compounds without cannabis cells was licensed to a company spun-off from the lab that developed the process.
-
Synthetic Bio Chemicals Start-Up Gains $5M in Early Funds
A new enterprise using digital and synthetic biology to create sustainable chemicals at industrial scale is raising $5 million in pre-seed round funds.
-
Infant Gut Microbiome Biomarker Study Underway
A clinical study has begun analyzing infants’ stool samples to determine the characteristics of healthy microbial communities in young children.
-
Univ. Labs Ink Licensing Deals for Covid-19 Tests
Two companies agreed to license technologies from academic labs in the U.S. and U.K. for developing faster and more sensitive at-home tests for Covid-19 infections.
-
Immune Disease Biotech Acquired in $405M Deal
A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences.
-
Peptide Vaccine Shown to Reduce Harmful Cholesterol
Tests with lab monkeys show a vaccine with a synthetic peptide lowers so-called bad cholesterol in blood for longer periods than a comparable monoclonal antibody.
-
Biotech Start-Up Demonstrates Cancer Therapy, Raises $6.4M
A new biotechnology company demonstrated in lab mice its therapy for glioblastoma, an aggressive brain cancer, that overcomes limitations of current treatments.
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Trial Okayed for Engineered Cell Cancer Therapy
A clinical trial is set to begin testing engineered immune-system cells designed to precisely target and infiltrate cancerous tumors without other potentially toxic proteins.
-
Precision Protein Design Start-Up Gains $40M in Early Funds
A start-up company designing and testing precise proteins within live animals to speed creation of new therapeutics is raising $40 million in its first venture round.